On Jul. 3, 2020, Gilead Sciences announced the European Commission had granted conditional marketing authorization for Vekluryﾮ (remdesivir) as a treatment for SARS-CoV-2 infection. The conditional marketing authorization was granted in the interest of public health due to the COVID-19 pandemic and was based on a rolling review of supporting data that began in Apr. 2020.